10-Q: Bio-Path Holdings Reports Positive Interim Phase 2 Data and Secures $7.2 Million in Financing

Bio-Path Holdings announced positive interim results from its Phase 2 clinical trial for prexigebersen in AML and secured $7.2 million in financing during the second quarter of 2024.

Summary

• Bio-Path Holdings, a clinical-stage oncology company, released its financial results for the quarter ended June 30, 2024.
• The company reported a net loss of $1.9 million for the three months ended June 30, 2024, and a net loss of $5.0 million for the six months ended June 30, 2024.
• Research and development expenses decreased to $1.9 million for the three months and $4.2 million for the six months ended June 30, 2024, primarily due to reduced manufacturing costs.
• The company successfully raised $7.2 million through various financing activities during the first half of 2024.
• Interim data from the Phase 2 clinical trial of prexigebersen in AML showed a 75% complete remission rate in newly diagnosed patients and a 55% complete remission rate in relapsed/refractory patients.
• The company is also progressing its other drug candidates, BP1002, BP1003, and BP1001-A, through clinical trials and preclinical studies.
• Bio-Path Holdings had a cash balance of $4.0 million as of June 30, 2024, but management has expressed doubt about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. The clinical trial results are very promising, but the company's financial situation and going concern warning temper the positive outlook. The company has raised significant capital but still needs more to continue operations.

Positives

• The company successfully raised $7.2 million in the first half of 2024, strengthening its financial position.
• Interim data from the Phase 2 clinical trial of prexigebersen in AML showed very promising results, with high complete remission rates.
• The company is progressing multiple drug candidates through clinical trials and preclinical studies.
• The company has completed the first two dose cohorts of the BP1002 Phase 1/1b clinical trial.
• The company has completed the first dose cohort of the BP1001-A Phase 1/1b clinical trial.

Negatives

• The company reported a net loss of $1.9 million for the three months and $5.0 million for the six months ended June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's cash balance of $4.0 million may not be sufficient to meet obligations for the next 12 months.
• The company is still in the clinical stage and has not generated significant revenue to date.
• The company is subject to certain restrictions on its ability to offer and sell shares of its common stock under the At The Market Offering Agreement.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company is subject to the risks associated with drug development, including clinical trial delays and failures.
• The company may not be able to obtain regulatory approval for its drug candidates.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's common stock could be delisted from the Nasdaq Capital Market if it fails to meet continued listing requirements.
• The company is subject to the risk of cyber-attacks and other breaches of its systems.

Future Outlook

The company expects to continue to incur significant operating expenses and will require substantial additional capital to fund its projected operating requirements. The company plans to continue enrollment in the Phase 2 clinical trial for prexigebersen and pursue FDA expedited programs for Fast Track designation. The company is also evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• Management believes that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, focusing on developing novel RNAi nanoparticle drug candidates for cancer treatment. The company's focus on AML and other cancers aligns with the growing need for effective therapies in these areas. The company is also exploring the use of prexigebersen for obesity, which is a growing area of interest in the pharmaceutical industry.

Comparison to Industry Standards

• The CR/CRi rate of 86% for newly diagnosed AML patients in the prexigebersen trial is significantly higher than the 54-74% range reported for frontline decitabine and venetoclax combination therapy.
• The CR/CRi rate of 57% for relapsed/refractory AML patients in the prexigebersen trial is significantly higher than the 12-52% range reported for decitabine and venetoclax combination therapy.
• The company's approach of using RNAi nanoparticle technology is a novel approach in the industry, with potential advantages over traditional small molecule inhibitors.
• The company's focus on developing molecular biomarker packages is in line with the industry trend of personalized medicine.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the potential for stock dilution.
• Employees may be impacted by the company's financial stability and the potential for job security issues.
• Patients may benefit from the company's drug development efforts, particularly if the clinical trials are successful.
• Creditors may be impacted by the company's ability to repay its debts.

Next Steps

• The company plans to continue enrollment in the Phase 2 clinical trial for prexigebersen.
• The company plans to pursue FDA expedited programs for Fast Track designation for prexigebersen.
• The company is evaluating whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.
• The company expects to advance to the next planned higher dose of 60 mg/m2 in the BP1002 Phase 1/1b clinical trial in the fourth quarter of 2024.
• The company expects to complete enrollment in the second dose cohort of the BP1001-A Phase 1/1b clinical trial by the end of 2024.
• The company plans to file an IND application and initiate the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors.

Key Dates

Keywords

RNAi, nanoparticle, oncology, clinical trial, AML, prexigebersen, BP1002, BP1003, BP1001-A, financing, biotechnology, drug development